| NCT00805376 |
DNX2401 (Formerly Known as Delta-24-RGD-4C) + TMZ |
Phase I |
Ad.Delta-24-RGD-4C |
Drug: DNX-2401 |
| Procedure: Tumor Removal |
| * Completed |
| NCT02197169 |
DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors (TARGET-I) |
Phase I |
CRAd DNX-2401 (Formerly Named Delta-24-RGD) |
Drug: Single intratumoral injection of DNX-2401 |
| Drug: Interferon-gamma |
| * In the process of recruiting participants |
| NCT03072134 |
Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma |
Phase I |
Neural stem cells loaded with Ad5-pK7 |
Biological: Neural stem cells loaded with Ad5-pK7 |
| * In the process of recruiting participants |
| NCT02798406 |
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects |
Phase II |
CRAd DNX-2401 |
Biological: DNX-2401 and pembrolizumab |
| * In the process of recruiting participants |
| NCT01301430 |
Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme |
Phase I/II |
Parvovirus H-1 |
Drug: H-1PV |
| * Completed |
| NCT01582516 |
Trial of a Conditionally Replication-competent Adenovirus (Delta-24-rgd) Administered by Convection Enhanced Delivery in Patients With Recurrent Glioblastoma |
Phase I/II |
Ad.Delta-24-RGD |
Biological: delta-24-RGD adenovirus |
| * Completed |
| NCT01956734 |
Virus DNX2401 and Temozolomide in Recurrent Glioblastoma (D24GBM) |
Phase I |
DNX-2401 (Formerly Named Delta-24-RGD) |
Procedure: DNX2401 and Temozolomide |
| * Ongoing trial |
